Michael Lincoff of the Cleveland Clinic highlighted during the American Heart Association 2023 Scientific Sessions that semaglutide is the first weight management therapy proven, through rigorous randomised controlled trials, to reduce the risk of cardiovascular events
OBESITY EPIDEMIC Obesity is a multi-causal chronic disease of excess adiposity that increases the risk of other diseases, including type 2 diabetes (T2D), hypertension, and cardiovascular disease (CVD)
In the monotherapy placebo-controlled study (SURPASS-1), treatment with tirzepatide 10 mg resulted in significantly greater SBP reductions compared with placebo (estimated treatment difference [ETD] [95% CI] 3.1 [ 6.2, 0.1] mmHg
Within that wider approach, some formulas target the gut side of the appetite system directly
This doesnt happen because of one meal or one spike
Improved side effects : Many patients report that nausea and bloating are noticeably better by week three